Please login to the form below

Not currently logged in
Email:
Password:

rifaximin

This page shows the latest rifaximin news and features for those working in and with pharma, biotech and healthcare.

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some

Latest news

  • FDA approves two new IBS medicines FDA approves two new IBS medicines

    The FDA has approved two new treatments for irritable bowel syndrome with diarrhoea (IBS-D) in the form of Actavis' Viberzi (eluxadoline) and Salix' Xifaxan (rifaximin).

  • Valeant raises offer for Salix; rival Endo bows out Valeant raises offer for Salix; rival Endo bows out

    The Canadian company is banking on the future success of Salix' traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), which is in the final stages of FDA review for the

  • Endo tries to ride out Valeant with $15.7bn bid for Salix Endo tries to ride out Valeant with $15.7bn bid for Salix

    Salix would give it an entry into the gastrointestinal therapy category, bringing in products such as traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products like

  • Valeant swoops on Salix with $10bn takeover deal Valeant swoops on Salix with $10bn takeover deal

    Adding Salix to the fold will bring in traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products such as diabetes therapy Glumetza (extended-release metformin) that

  • Norgine close to final yes from NICE on Targaxan Norgine close to final yes from NICE on Targaxan

    The drug-pricing watchdog is recommending that Norgine's Targaxan ( rifaximin) be funded as a treatment option for preventing recurrent episodes of hepatic encephalopathy, a brain condition caused by liver failure. ... Rifaximin can prevent these

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics